Live Vital Review: It Calls Retatrutide 'Off-Label' — There Is No Label. It Is an Unapproved Investigational Drug.

What Is Live Vital?

Live Vital LLC operates a telehealth peptide clinic serving all 50 states, with the affiliate programme listed as launched on 2 June 2026 — around two months old at the time of this review. It names its physician, Dr Patrick Taylor, MD, offers a free 15-minute phone consult, and states that medications are 'compounded at 503A-licensed pharmacies'. We could locate no BBB profile or independent review record.

The catalogue is organised by goal. For skin: GHK-Cu copper peptide at $99 a month, and two compounded blends — Glow (GHK-Cu, BPC-157, TB-500) and Klow (the same plus KPV) at $149. For recovery and longevity: Wolverine (BPC-157 and TB-500) at $116, BPC-157 and TB-500 individually at $99 each, CJC-1295/Ipamorelin at $116, injectable NAD+ at $83 and glutathione at $66. For weight and metabolism: tesamorelin at $166, MOTS-c at $149, and retatrutide at $299.

Presentation is genuinely good. Prices are published for every product, each protocol names its constituent peptides rather than hiding behind a blend name, unlimited messaging is included, and the free phone consult with a named doctor is more access than most competitors offer. On the mechanics of running a clinic, Live Vital does several things right.

The problem is what is being sold. Most of this catalogue consists of research peptides with little or no human clinical evidence and no FDA approval for any use. One of them, BPC-157, has been specifically evaluated by the FDA and found to raise safety concerns for compounding. And one — retatrutide — is an investigational drug that cannot lawfully be compounded at all.

That is the subject of most of this review, because it is the thing a buyer most needs to understand and the thing the product page describes incorrectly.

The Catalogue, Its Prices and Its Regulatory Status

The pricing is transparent and the constituent peptides are named, which we credit — several competitors sell 'proprietary blends' without saying what is in them. What the price column cannot tell you is that almost nothing here has been approved by the FDA for any indication, and that the products differ enormously in regulatory standing. Tesamorelin is a genuinely approved drug being used off-label, which is ordinary medicine. BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, KPV and injectable GHK-Cu are research peptides with no approval and limited human data. Retatrutide is in a different category again — an investigational drug in active clinical trials that has never been approved anywhere in the world.

Unapproved, Uncompoundable and Mislabelled — What's Really Being Sold

Retatrutide needs to be addressed directly, because Live Vital's own description of it is wrong in a way that matters.

The product page states retatrutide is 'prescribed off-label under physician supervision. Not FDA-approved.' Off-label prescribing is a well-defined thing: it means a clinician uses a drug that the FDA has approved, for a patient or purpose outside its approved labelling. Tesamorelin, elsewhere in this same catalogue, is a proper example — it is approved as Egrifta for HIV-associated lipodystrophy, and prescribing it for abdominal fat in someone without HIV is genuine off-label use. Retatrutide is not that. It has no label to be off. It has never been approved by the FDA or any other regulator, for anything.

Retatrutide is an Eli Lilly investigational compound, currently in Phase 3 trials. Reporting indicates Lilly plans to file for approval in early 2027, with a realistic approval window of late 2027 to early 2028. Lilly's own position is that retatrutide is legally available only through its clinical trials, and that anything sold to consumers outside those trials is illegal, with no way to verify safety, purity or dosing.

It also cannot lawfully be compounded, and the reason is worth understanding. Compounded semaglutide and tirzepatide became widely available because they are components of FDA-approved drug products, which brought them within compounding rules during shortages. Retatrutide has no approved version, no USP monograph, and does not appear on the FDA's bulk drug substance lists — so none of those routes applies. The FDA has issued more than fourteen warning letters to retatrutide vendors since December 2024, and a CBS News investigation documented over 120 websites and more than 50 clinics selling or promoting it.

What that means practically for a buyer: whatever arrives at $299 a month is not Lilly's clinical trial material. It is made from bulk peptide of unverifiable origin, and neither its identity, its purity nor its dose can be confirmed by you or, realistically, by the prescriber.

BPC-157 deserves its own note. The FDA has formally evaluated it for compounding and identified specific safety risks: BPC-157 is a common name rather than a United States Adopted Name, and the FDA has encountered multiple different salts and derivatives sold commercially under that same common name — creating, in its assessment, a risk that patients are dosed with a different substance from the one the physician ordered. There is also no USP monograph for BPC-157 free base or its acetate salt, meaning no standard for identity or purity. Substances the FDA places in Category 2 raise significant safety risks and are excluded from its enforcement discretion, meaning the agency would consider acting against a compounder using them.

TB-500, CJC-1295, Ipamorelin and MOTS-c are likewise unapproved, with human evidence ranging from thin to essentially absent. Several are prohibited in competitive sport under WADA rules — relevant if you are tested.

The Consultation Process

Eligibility

• •Adults, in all 50 states, following a medical intake and clinical qualification.
• •Anyone considering retatrutide should understand it is an unapproved investigational drug. If you want a triple-agonist, the lawful route is enrolment in one of Lilly's clinical trials, where the material is verified and you are monitored. If you want an approved GLP-1, tirzepatide and semaglutide are available as Zepbound, Mounjaro, Wegovy and Ozempic.
• •GLP-1-class drugs including retatrutide can cause severe gastrointestinal effects, and the safety profile of retatrutide outside trial conditions is by definition uncharacterised. Contraindications established for approved GLP-1s — personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy — should be assumed to apply and probably understate the risk given the unknown provenance.
• •BPC-157 carries the FDA-identified risk that products sold under that name may be different salts or derivatives, so you may not receive what was prescribed.
• •Growth hormone secretagogues including CJC-1295, Ipamorelin and tesamorelin raise IGF-1. They should not be used by anyone with active malignancy, and cancer survivors should decide alongside an oncologist. They can also affect glucose tolerance.
• •Injectable NAD+ carries the caution the FDA has raised industry-wide: it has warned that compounders have used food-grade NAD+ to make injectable products, and that food-grade ingredients 'are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins'.
• •Several of these peptides are prohibited substances in competitive sport under WADA rules. If you are drug tested for athletics, do not use them.
• •Do not use any of these in pregnancy or while breastfeeding.
• •Injectable products carry infection risk. Sterile technique matters, and with compounded peptides from uncertain sources so does the sterility of the preparation itself.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Shipped directly to patients. Terms were not published on the pages we reviewed.

• •Every product priced publicly, with no gated pricing
• •Blends name their constituent peptides rather than hiding behind a brand name
• •A named physician, Dr Patrick Taylor, MD
• •Free 15-minute phone consult before purchase
• •Unlimited messaging included with every plan
• •States plainly that retatrutide is not FDA-approved
• •Tesamorelin is a legitimately approved drug used off-label — ordinary medicine
• •Serves all 50 states
• •Clear organisation by goal rather than by product name

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Live Vital May Be Best For

• •We do not recommend this provider, and the retatrutide product in particular
• •If you want a triple-agonist, the lawful and monitored route is an Eli Lilly clinical trial
• •If you want an effective GLP-1, approved options exist — Zepbound, Wegovy, Mounjaro and Ozempic
• •If you want tesamorelin specifically, that is a legitimate approved drug worth discussing with any physician

Limitations

• •The retatrutide listing is the reason for this rating and we want to be exact about why. Live Vital calls it 'prescribed off-label under physician supervision. Not FDA-approved.' The second sentence is true. The first is not a description that can apply to this drug. Off-label means an approved drug used outside its approved labelling — the label exists, the FDA has reviewed the molecule, its manufacturing is regulated, and a clinician is exercising judgement about indication. Retatrutide has none of that. It is in Phase 3, unapproved everywhere, and Lilly states it is legally available only through its trials. Using the phrase 'off-label' borrows the legitimacy of ordinary medical practice for something categorically different, and a reader who knows that off-label prescribing is routine and lawful would be badly misled.
• •The compounding position closes off the obvious defence. Semaglutide and tirzepatide could be compounded because they are components of approved drug products. Retatrutide has no approved version, no USP monograph and no place on the FDA's bulk drug substance lists — so there is no lawful pathway for a 503A pharmacy to prepare it. Live Vital's own footer states that its medications are 'compounded at 503A-licensed pharmacies', which makes the contradiction its own. The FDA has issued more than fourteen warning letters to retatrutide vendors since December 2024, and reporting indicates many carried on selling anyway.
• •For the buyer, the practical consequence is the one that matters. You are paying $299 a month for an injectable whose contents cannot be verified. There is no reference standard, no monograph, no approved product to compare against, and no way for you or the prescriber to confirm that the vial contains retatrutide, at the stated concentration, free of contaminants. The published trial results — which are genuinely impressive — describe Lilly's material under trial conditions, and tell you nothing about what arrives in the post.
• •BPC-157 is a smaller version of the same problem and worth knowing about independently. The FDA has evaluated it and flagged that 'BPC-157' is a common name rather than an official one, that multiple different salts and derivatives are sold commercially under it, and that this creates a risk of patients being dosed with a substance other than the one prescribed — compounded by the absence of any USP monograph setting a standard for identity or purity.
• •It is worth saying what Live Vital does well, because the presentation is genuinely better than much of this market: published prices, named peptides in every blend, a named physician, a free consult before you spend anything, and unlimited messaging. Under different circumstances that would be a good clinic. The issue is not how the service is run. It is that a substantial part of what it sells has no approval, no monograph, little human evidence, and in one case no lawful route to existence.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Live Vital presents well. It publishes a price for every protocol, names the peptides inside each blend instead of hiding behind a brand, gives you a named physician and a free fifteen-minute call before you spend anything, and includes unlimited messaging. Several far better-known providers in this series do none of those things.

But the product it markets as 'Exclusive' at $299 a month is retatrutide, and its own description of that product is wrong in a way that matters. Calling it 'prescribed off-label' borrows the legitimacy of ordinary medical practice — which is lawful, routine and well understood — for something categorically different. Off-label use requires an approved drug with a label. Retatrutide has never been approved by any regulator anywhere. It is an Eli Lilly investigational compound in Phase 3, and Lilly states it is legally available only through its clinical trials.

It also cannot lawfully be compounded. Semaglutide and tirzepatide could be, because they are components of approved drug products. Retatrutide has no approved version, no USP monograph and no place on the FDA's bulk substance lists — and the FDA has sent more than fourteen warning letters to vendors selling it since December 2024. Live Vital's own footer says its medications are compounded at 503A pharmacies, which is precisely the contradiction.

For anyone considering it, the consequence is simple: you would be paying $299 a month to inject something whose identity, concentration and purity cannot be verified by anyone, against published trial results generated with a different, controlled material you are not receiving.

BPC-157 carries a smaller version of the same problem — the FDA has flagged that products sold under that name may be different salts or derivatives, with no monograph to define what you should be getting.

We rate Live Vital 2.0 out of 5 — a well-presented clinic selling a catalogue built largely on unapproved research peptides, headed by a drug that has no lawful route to your door.

If you want a triple-agonist, ask about a Lilly trial. If you want effective weight-loss treatment now, approved options exist with evidence that actually applies to what you receive. This review is informational only and is not medical advice — speak to a licensed clinician before starting, changing or stopping any treatment.